Literature DB >> 19802891

Simulations of measured photobleaching kinetics in human basal cell carcinomas suggest blood flow reductions during ALA-PDT.

Ken Kang-Hsin Wang1, William J Cottrell, Soumya Mitra, Allan R Oseroff, Thomas H Foster.   

Abstract

BACKGROUND AND
OBJECTIVE: In a recently completed pilot clinical study at Roswell Park Cancer Institute, patients with superficial basal cell carcinoma (sBCC) received topical application of 20% 5-aminolevulinic acid (ALA) and were irradiated with 633 nm light at 10-150 mW cm(-2). Protoporphyrin IX (PpIX) photobleaching in the lesion and the adjacent perilesion normal margin was monitored by fluorescence spectroscopy. In most cases, the rate of bleaching slowed as treatment progressed, leaving a fraction of the PpIX unbleached despite sustained irradiation. To account for this feature, we hypothesized a decrease in blood flow during ALA-photodynamic therapy (PDT) that reduced the rate of oxygen transported to the tissue and therefore attenuated the photobleaching process. We have performed a detailed analysis of this hypothesis. STUDY DESIGN/
MATERIALS AND METHODS: We used a comprehensive, previously published mathematical model to simulate the effects of therapy-induced blood flow reduction on the measured PpIX photobleaching. This mathematical model of PDT in vivo incorporates a singlet-oxygen-mediated photobleaching mechanism, dynamic unloading of oxygen from hemoglobin, and provides for blood flow velocity changes. It permits simulation of the in vivo photobleaching of PpIX in this patient population over the full range of irradiances and fluences.
RESULTS: The results suggest that the physiological equivalent of discrete blood flow reductions is necessary to simulate successfully the features of the bleaching data over the entire treatment fluence regime. Furthermore, the magnitude of the blood flow changes in the normal tissue margin and lesion for a wide range of irradiances is consistent with a nitric-oxide-mediated mechanism of vasoconstriction.
CONCLUSION: A detailed numerical study using a comprehensive PDT dosimetry model is consistent with the hypothesis that the observed trends in the in vivo PpIX photobleaching data from patients may be explained on the basis of therapy-induced blood flow reductions at specific fluences. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19802891      PMCID: PMC2805271          DOI: 10.1002/lsm.20847

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  29 in total

1.  Tumor blood-flow changes following protoporphyrin IX-based photodynamic therapy in mice and humans.

Authors:  M A Herman; D Fromm; D Kessel
Journal:  J Photochem Photobiol B       Date:  1999 Sep-Oct       Impact factor: 6.252

2.  The cutaneous uptake of atmospheric oxygen contributes significantly to the oxygen supply of human dermis and epidermis.

Authors:  M Stücker; A Struk; P Altmeyer; M Herde; H Baumgärtl; D W Lübbers
Journal:  J Physiol       Date:  2002-02-01       Impact factor: 5.182

3.  Porphyrin bleaching and PDT-induced spectral changes are irradiance dependent in ALA-sensitized normal rat skin in vivo.

Authors:  J C Finlay; D L Conover; E L Hull; T H Foster
Journal:  Photochem Photobiol       Date:  2001-01       Impact factor: 3.421

4.  Quantitative model calculation of the time-dependent protoporphyrin IX concentration in normal human epidermis after delivery of ALA by passive topical application or lontophoresis.

Authors:  Willem M Star; Maurice C G Aalders; Arnoldo Sac; Henricus J C M Sterenborg
Journal:  Photochem Photobiol       Date:  2002-04       Impact factor: 3.421

5.  Pain caused by photodynamic therapy of skin cancer.

Authors:  S Grapengiesser; M Ericson; F Gudmundsson; O Larkö; A Rosén; A-M Wennberg
Journal:  Clin Exp Dermatol       Date:  2002-09       Impact factor: 3.470

Review 6.  The present and future role of photodynamic therapy in cancer treatment.

Authors:  Stanley B Brown; Elizabeth A Brown; Ian Walker
Journal:  Lancet Oncol       Date:  2004-08       Impact factor: 41.316

7.  A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (Ametop) for pain relief during topical photodynamic therapy.

Authors:  M V Holmes; R S Dawe; J Ferguson; S H Ibbotson
Journal:  Br J Dermatol       Date:  2004-02       Impact factor: 9.302

8.  Kinetics of the superficial perfusion and temperature in connection with photodynamic therapy of basal cell carcinomas using esterified and non-esterified 5-aminolaevulinic acid.

Authors:  S Pålsson; L Gustafsson; N Bendsoe; M Soto Thompson; S Andersson-Engels; K Svanberg
Journal:  Br J Dermatol       Date:  2003-06       Impact factor: 9.302

9.  Monitoring ALA-induced PpIX photodynamic therapy in the rat esophagus using fluorescence and reflectance spectroscopy.

Authors:  Bastiaan Kruijt; Henriette S de Bruijn; Angelique van der Ploeg-van den Heuvel; Ron W F de Bruin; Henricus J C M Sterenborg; Arjen Amelink; Dominic J Robinson
Journal:  Photochem Photobiol       Date:  2008-06-13       Impact factor: 3.421

10.  Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy.

Authors:  B W Henderson; S M Waldow; T S Mang; W R Potter; P B Malone; T J Dougherty
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

View more
  10 in total

1.  Improved micro-distribution of antibody-photon absorber conjugates after initial near infrared photoimmunotherapy (NIR-PIT).

Authors:  Tadanobu Nagaya; Yuko Nakamura; Kazuhide Sato; Toshiko Harada; Peter L Choyke; Hisataka Kobayashi
Journal:  J Control Release       Date:  2016-04-05       Impact factor: 9.776

2.  Measuring the Physiologic Properties of Oral Lesions Receiving Fractionated Photodynamic Therapy.

Authors:  Shannon M Gallagher-Colombo; Harry Quon; Kelly M Malloy; Peter H Ahn; Keith A Cengel; Charles B Simone; Ara A Chalian; Bert W O'Malley; Gregory S Weinstein; Timothy C Zhu; Mary E Putt; Jarod C Finlay; Theresa M Busch
Journal:  Photochem Photobiol       Date:  2015-07-02       Impact factor: 3.421

3.  A theoretical comparison of macroscopic and microscopic modeling of singlet oxygen during Photofrin and HPPH mediated-PDT.

Authors:  Baochang Liu; Michele M Kim; Timothy C Zhu
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2013-02-02

4.  Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema.

Authors:  Srivalleesha Mallidi; Sriram Anbil; Seonkyung Lee; Dieter Manstein; Stefan Elrington; Garuna Kositratna; David Schoenfeld; Brian Pogue; Steven J Davis; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2014-02       Impact factor: 3.170

5.  Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses.

Authors:  Allison Marrero; Theresa Becker; Ulas Sunar; Janet Morgan; David Bellnier
Journal:  Photochem Photobiol       Date:  2011-06-13       Impact factor: 3.421

6.  Explicit dosimetry for photodynamic therapy: macroscopic singlet oxygen modeling.

Authors:  Ken Kang-Hsin Wang; Jarod C Finlay; Theresa M Busch; Stephen M Hahn; Timothy C Zhu
Journal:  J Biophotonics       Date:  2010-06       Impact factor: 3.207

7.  A light emitting diode (LED) based spatial frequency domain imaging system for optimization of photodynamic therapy of nonmelanoma skin cancer: quantitative reflectance imaging.

Authors:  R B Saager; D J Cuccia; S Saggese; K M Kelly; A J Durkin
Journal:  Lasers Surg Med       Date:  2013-04       Impact factor: 4.025

Review 8.  Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?

Authors:  Yuko Nakamura; Ai Mochida; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2016-09-02       Impact factor: 4.774

Review 9.  Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?

Authors:  Hisataka Kobayashi; Rira Watanabe; Peter L Choyke
Journal:  Theranostics       Date:  2013-12-11       Impact factor: 11.556

Review 10.  Cancer drug delivery: considerations in the rational design of nanosized bioconjugates.

Authors:  Hisataka Kobayashi; Baris Turkbey; Rira Watanabe; Peter L Choyke
Journal:  Bioconjug Chem       Date:  2014-11-19       Impact factor: 4.774

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.